Clinical trials have demonstrated controversial results, as exemplified by the successful results with an FGF21 analog [286] and the less-than-expected results obtained with exogenous leptin in non-hereditary obesity (in the absence of concomitant dietary energy restriction) [288]. This evidence concerns the gene FGF21 and obesity disorder.